ReNeuron Group plc Investor presentations
25 February 2021 - 6:01PM
RNS Non-Regulatory
TIDMRENE
ReNeuron Group plc
25 February 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Investor presentations
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, announces it will be
presenting at three investor events, providing an overview of the
business and the progress being made by the Company as it focuses
on its retinal disease programme and exosome and iPSC
platforms.
Proactive One2One Investor Forum
ReNeuron will present at today's Proactive One2One Investor
Forum, commencing at 6.00pm, with ReNeuron presenting at this time.
The event brings together high net worth investors and private
investors with an interest in growth stocks. Investors can register
to attend the event here:
https://www.proactiveinvestors.co.uk/register/event_details/319
Shares Investor Evening Webinar
ReNeuron will present at the Shares Investor Evening Webinar, on
Tuesday 2 March 2021. Shares Spotlight webinars feature
presentations from directors of listed companies explaining their
investment propositions followed by an opportunity for investors to
ask questions. The event will commence at 6.00pm and ReNeuron will
present at 6.55pm. Investors can register to attend the event here:
https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-020321
H.C. Wainwright Global Life Sciences Conference
The Company will present at the H.C. Wainwright Global Life
Sciences Virtual Conference which is taking place on 9-10 March
2021. The conference will consist of panel discussions, company
presentations, virtual events, and networking opportunities. The
presentation will be available on demand during the conference.
Investors can register for the conference here:
https://hcwevents.com/globalconference/#toggle-id-1-closed
No new material information will be disclosed, and the
presentations will be made available on the Company website shortly
after the events here:
http://www.reneuron.com/investors/presentations/
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Michael Hunt, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker)
James Reeve/George Payne (Corporate
Finance)
Tim Sohal (Sales & Corporate Broking) +44 (0)20 3328 5656
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the brain. he Company also has the ability through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform to make any tissue cells of choice; in-house programmes
are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUSABRARUUUAR
(END) Dow Jones Newswires
February 25, 2021 02:01 ET (07:01 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024